SCHEMBL16201384

SCHEMBL16201384

CCCN(C)Cc1n[nH]cc1-c1ccc(OC(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT3 O60678 1/20 0.40
CARM1 Q86X55 1/20 0.40
PRMT6 Q96LA8 1/20 0.40
PRMT1 Q99873 1/20 0.40
PRMT8 Q9NR22 1/20 0.40
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
MAPK1 P28482 1/20 0.32
DRD1 P21728 1/20 0.32
PDE2A O00408 1/20 0.32
CRHR1 P34998 1/20 0.32
KDM2B Q8NHM5 1/20 0.32
HTT P42858 3/20 0.31
CYP19A1 P11511 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
DAGLA Q9Y4D2 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201228 0.89 PRMT1 (0.52) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16201340 0.83 TDO2 (0.33) ALDH1A1AGTR1AGTR2
SCHEMBL16201364 0.83 PRMT6 (0.44) PRMT6PRMT1CYP2C9CYP2C19
SCHEMBL16201444 0.81 LTA4H (0.41) LMNAMAPTHTTAGTR1AGTR2
SCHEMBL16201371 0.81 NPSR1 (0.39) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16201380 0.81 CRHR1 (0.36) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16201345 0.81 PRMT3 (0.40) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16201358 0.80 PRMT6 (0.39) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16201369 0.80 HRH3 (0.40) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16201425 0.79 AGTR1 (0.35) PRMT3CARM1PRMT6PRMT1PRMT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PRMT3 2/4885CARM1 11/4885PRMT6 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.